Primary information |
---|
ID | antitb_1198, |
Name | 24915878 |
N-Terminal modification | Pinanediol PD-protected Boropentapeptide |
C-Terminal Modification | AVKAA-BO2(PD) |
Chemical Modification | Free |
Linear/Cyclic | Conjugated with Boronic acid and pinanediol PD |
Length | Conjugated with Boronic acid and pinanediol PD |
Chirality | Linear |
Nature | 5 |
Source | L |
Species | Synthetic |
Inhibition Concentration | Mycobacterium thermoresistible |
In Vitro/ In vivo | Mycobacterium thermoresistible |
Cell Line | IC50 = 121.6 ± 25.3 μM for MycP1 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
Other activities | Mycosin protease-1 (MycP1) |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1199, |
Name | 24915878 |
N-Terminal modification | Pinanediol PD-protected Boropentapeptide |
C-Terminal Modification | AVKAA-BO2(PD) |
Chemical Modification | Free |
Linear/Cyclic | Conjugated with Boronic acid and pinanediol PD |
Length | Conjugated with Boronic acid and pinanediol PD |
Chirality | Linear |
Nature | 5 |
Source | L |
Species | Synthetic |
Inhibition Concentration | Mycobacterium smegmatis |
In Vitro/ In vivo | Mycobacterium smegmatis |
Cell Line | IC50 = 93.2±33.7 μM for MycP2 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
Other activities | Mycosin protease-1 (MycP1) |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1200, |
Name | 24915878 |
N-Terminal modification | Pinanediol PD-protected Boropentapeptide |
C-Terminal Modification | AVKAA-BO2(PD) |
Chemical Modification | Free |
Linear/Cyclic | Conjugated with Boronic acid and pinanediol PD |
Length | Conjugated with Boronic acid and pinanediol PD |
Chirality | Linear |
Nature | 5 |
Source | L |
Species | Synthetic |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis |
Cell Line | IC50 = 37.9±5.2 μM for MycP3 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
Other activities | Mycosin protease-1 (MycP1) |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |